Helicobacter infection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sun, 31 May 2026 04:02:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Helicobacter infection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Metronidazole, Bismuth Oxide and Tetracycline Hydrochloride Fixed‑Dose Combination vs Standard First‑line Therapy for Adults with Helicobacter pylori Infection https://clinicaltrials.eu/trial/metronidazole-bismuth-oxide-and-tetracycline-hydrochloride-fixed-dose-combination-vs-standard-first-line-therapy-for-adults-with-helicobacter-pylori-infection/ Sun, 31 May 2026 04:02:42 +0000 https://clinicaltrials.eu/trial/metronidazole-bismuth-oxide-and-tetracycline-hydrochloride-fixed-dose-combination-vs-standard-first-line-therapy-for-adults-with-helicobacter-pylori-infection/ The trial enrolls adults who have Helicobacter pylori infection, a bacterial condition that can lead to stomach ulcers and discomfort. The purpose is to determine whether a new fixed‑dose combination treatment is not worse than the standard first‑line therapy for eliminating the infection.

The new test medication combines three ingredients: Metronidazole, Bismuth oxide and Tetracycline hydrochloride. The standard regimen used for comparison contains a proton‑pump inhibitor (Esomeprazole) together with two antibiotics, Clarithromycin and Amoxicillin, plus metronidazole.

Participants take the assigned pills for about two weeks, after which they undergo a breath test called the Urea Breath Test that checks for the presence of the bacteria. Follow‑up visits record any side effects, how well the medication was taken, and whether the infection has been cleared.

]]>